Angiostatin endostatin gene therapy (Oxford BioMedica)

N/A

Report date: 2023/10/26 17:12:04

Base Information

Drug NameAngiostatin endostatin gene therapy (Oxford BioMedica)
Drug Alias NameEndoAngio-GTEIAV.endostatinEIAV.angiostatinAngiostatin endostatin gene therapyEndostatin lentivector gene therapy +[7] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionAngiogenesis inhibitorsGene transference
TargetsNot applicable
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOxford Biomedica
China Registration ClassN/A

Develop Information

Active CompaniesOxford BiomedicaSanofi
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A